Rethinking Management Strategies for Proliferative Diabetic Retinopathy

Seenu M. HariprasadPractical Retina Co-EditorFor this Practical Retina column, Peter H. Tang, MD, PhD, and Diana V. Do, MD, were asked to comment on the evolving paradigm for treating diabetic retinopathy (DR).Frequent discussion takes place regarding the current management of DR (especially proliferative diabetic retinopathy [PDR]) given the recent approval of anti-vascular endothelial growth factor (VEGF) therapy for the treatment of DR without diabetic macular edema (DME). For instance, given the availability of ranibizumab (Lucentis; Genentech, South San Francisco, CA) to treat PDR, is

Source: Ophthalmic Surgery, Lasers and Imaging : the Official Journal of the International Society for Imaging in the Eye - April 19, 2018 Category: Opthalmology Authors: Peter H. Tang, MD, PhD Source Type: research